Brazil to produce generic Cellcept following Roche deal
This article was originally published in Scrip
Roche has struck an agreement with the Oswaldo Cruz Foundation (Fiocruz), a research organisation linked to the Brazilian health ministry, which will see the firm cut the price of its immunosuppressant Cellcept (mycophenolate mofetil) and transfer technology for the production of the drug.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.